Search clinical trials for: RTS,S/AS02D and RTS,S/AS02A

Total 2263 results

GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.

Malaria

Mozambique
GlaxoSmithKline

Completed

Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants

Malaria | Malaria Vaccines

Tanzania
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.

Plasmodium Falciparum

Kenya
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.

Malaria

Mozambique
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

Malaria

United States
GlaxoSmithKline

Completed

Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region

Malaria

Mozambique
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S (MAL019)

Malaria, Falciparum

United States
University of Oxford

Completed

Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults (RTSS)

Malaria Vaccine

Thailand
Michigan State University
Boston University; National Institute of Allergy and Infectious Diseases (NIAID) and other collaborators

Recruiting

RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi (RTSS/PBO)

Malaria, Malaria Vaccine, Insecticide-treated Bednets

Malawi
GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Completed

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Malaria

United States
GlaxoSmithKline

Completed

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Malaria

Ghana, Kenya
University of Oxford
National Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...

Completed

A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S

Plasmodium Falciparum Malaria

United Kingdom
GlaxoSmithKline
PATH

Completed

A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

Malaria

United States
University of Oxford

Completed

A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S

Plasmodium Falciparum Malaria

United Kingdom
PATH
GlaxoSmithKline; Kenya Medical Research Institute; US Army Medical Research Directorate-Africa... and other collaborators

Completed

RTS,S/AS01E Hypo-immuno-responsiveness Study

Plasmodium Falciparum

Kenya
National Institute of Allergy and Infectious Diseases...

Completed

An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV

HIV Infections

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults

Tuberculosis (TB)

Switzerland
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline and other collaborators

Completed

Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali

Plasmodium Falciparum Malaria

Mali
GlaxoSmithKline
Walter Reed Army Institute of Research (WRAIR); The PATH Malaria Vaccine Initiative...

Completed

Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Malaria

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaborators

Completed

Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine

Malaria, Falciparum

Kenya
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); The...

Completed

A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults

Malaria

United States
M.D. Anderson Cancer Center
Concordia Pharmaceuticals, Inc

Completed

FTS Study in Patients With Advanced Hematologic Malignancies

Leukemia | Myelodysplastic Syndrome

United States
London School of Hygiene and Tropical Medicine
Malaria Research and Training Center, Bamako, Mali; Institut de Recherche en...

Completed

Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) (RTSS-SMC)

Children, Only | Malaria,Falciparum

Burkina Faso, Mali
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline and other collaborators

Completed

FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali

Malaria | Plasmodium Falciparum Malaria

Mali
KEMRI-Wellcome Trust Collaborative Research Program
GlaxoSmithKline

Unknown

An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial (MAL059)

Malaria

Kenya
London School of Hygiene and Tropical Medicine
Malaria Research and Training Center, Bamako, Mali; Institut de Recherche en...

Completed

Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study (RTSS-SMC)

Child, Only | Malaria,Falciparum

Mali, Burkina Faso
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.

Tuberculosis (TB)

Belgium
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR); The PATH Malaria...

Completed

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

Malaria | Plasmodium Falciparum Malaria

United States
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); GlaxoSmithKline and other collaborators

Completed

Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali

Malaria

Mali
GlaxoSmithKline

Completed

Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children

Malaria

Ghana
Henogen
GlaxoSmithKline

Completed

Compare the Immune Response & Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine vs Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis & Dialysis Patients Who Did Not Respond to Previous Hepatitis B Vaccination

Hepatitis B

Belgium, Czech Republic, Hungary
Marcus Altfeld, M.D., Ph.D.
GlaxoSmithKline

Completed

Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)

HIV Infections

United States
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Completed

Phase I Pediatric FMP2.1/AS02A Trial in Mali

Plasmodium Falciparum Malaria

Mali
GlaxoSmithKline

Completed

Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.

Malaria

Kenya, Tanzania
University Hospital, Strasbourg, France

Active, not recruiting

Personalized Non-invasive Neuromodulation by rTMS for Chronic and Treatment Resistant Catatonia (RETONIC)

Schizophreniform Catatonia | Treatment Resistant

France
Shiga University
University of Chicago; Shionogi; Tokyo University; Showa University; Fukushima Medical... and other collaborators

Unknown

Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Japan
GlaxoSmithKline

Completed

Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine

Malaria

Mozambique
Centre for Addiction and Mental Health

Completed

rTMS and Cognitive Training in Youth Depression

Depression

Canada
U.S. Army Medical Research and Development Command
GlaxoSmithKline; United States Agency for International Development (USAID); Walter... and other collaborators

Completed

Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children

Plasmodium Falciparum Malaria

Kenya
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Shionogi

Completed

First-in-human Study of S-588210 (S-488210+S-488211)

Head and Neck Cancer | Esophageal Cancer | Lung Cancer | Mesothelioma | Bladder Cancer

United Kingdom
Abbott Medical Devices

Active, not recruiting

The CONFIDENCE Registry

Severe Aortic Stenosis | Symptomatic Degenerative Aortic Stenosis

Spain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
Henogen
GlaxoSmithKline

Completed

A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.

Hepatitis B

Belgium, Czech Republic, Hungary
SolAeroMed Inc.

Recruiting

Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis

Bronchiectasis | Cystic Fibrosis

Canada
European Organisation for Research and Treatment...

Unknown

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Melanoma (Skin)

France, Spain, Belgium, Germany, Italy, United Kingdom, Netherlands
Peking University Cancer Hospital & Institute

Recruiting

Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer (RESCUE-GC)

Gastric Cancer

China
National Institute of Allergy and Infectious Diseases...
Gritstone bio, Inc.

Completed

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

COVID-19

United States
El Zahraa Gamal

Not yet recruiting

Metabolic Profile as a Predictor of No-reflow in Diabetic Patients

Acute Myocardial Infarction (AMI)
Abbott Diagnostics Division

Completed

Abbott Laboratories Alinity s Blood Screening Assays - Clinical Evaluation Protocol

Healthy

United States
Sun Yat-sen University

Unknown

Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer (CAPITAL)

Gastric Cancer

China

Search clinical trials for: RTS,S/AS02D and RTS,S/AS02A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations